Nordic Nanovector ASA, of Oslo, Norway, entered into a collaboration with Legochem Bioscience Inc., of Daejeon, South Korea, to develop CD37-targeting antibody-drug conjugates to treat leukemias. This collaboration supports Nordic Nanovector's strategy to expand its pipeline of targeted therapies to include CD37-targeting antibody products conjugated to anti-cancer compounds that are not radionuclides. Deal terms were not disclosed.